Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

does drug testing after a high-scoring performance send a deeper message? ⁣ Stephen Jackson (Stak5) says: ‘the NBA be showin’ their hand.’ ⁣ ⁣ D. Mitchell: 71 | 11 | 8 (Drug Tested)⁣ L. Dončić: 60 | 21 | 10 (Not Drug Tested⁣)

513,054 Aufrufe • vor 3 Jahren •via X (Twitter)

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

The corruption of our medical system goes much deeper than you think. Alan Cassels just exposed how the American Heart Association manipulates health guidelines to “sell sickness” and turn healthy people into patients for profit. “The new definition of ‘high cholesterol’ is almost 100 million Americans.” “This is a massive market.” “The reason is so obvious.” “Because there’s so much money in it.” “The American Heart Association came out with a new set of guidelines just earlier this month.” “They are a fascinating study in the creation of disease.” “The recommendations around when you should test somebody for high cholesterol have changed.” “Instead of just testing older people, we should be testing younger people.” “We should be screening children.” “We should be getting people to submit to a cholesterol test every 5 years.” “There are new cholesterol-lowering drugs.” “There are new ways to take healthy people and turn them into candidates for whom the drug would be prescribed.” “I think cholesterol is one of the most absurd examples of the selling of sickness.” “The danger of high cholesterol has not changed.” “It’s a small risk factor.” “If you take a cholesterol-lowering drug for 10 years, it might reduce your risk of having a heart attack or stroke by about 1%, if you’re lucky.” “About 20-25% of the people who take the drug will not be able to tolerate it because of adverse effects.” “We’re talking about a drug that has an extremely low yield and a high likelihood of being harmful.” Alan Cassels Jeffrey A Tucker

Brownstone Institute

140,050 Aufrufe • vor 2 Monaten

How You Cheated 👇 Seven Pharma Firms that failed Drug Quality tests gave money to political parties through #ElectoralBonds. 📍𝐇𝐞𝐭𝐞𝐫𝐨 𝐋𝐚𝐛𝐬 𝐚𝐧𝐝 𝐇𝐞𝐭𝐞𝐫𝐨 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 Bought Electoral Bonds for Rs 40 crore in April 2022. In the preceding 10 months, the Maharashtra Food and Drug Administration issued six notices issued to the Hyderabad-based company for substandard drugs. At least three of them pertained to *** Remdesivir ***, an antiviral drug widely used to treat #Covid19. Two other products of Hetero were also found substandard in 2021: an antifungal medicine, Itbor capsule, and Monocef, used for Bacterial Infection. Such a violation could lead to the suspension of a company’s manufacturing licence. But the #Telangana regulator did not act against Hetero. 📍𝐓𝐨𝐫𝐫𝐞𝐧𝐭 𝐏𝐡𝐚𝐫𝐦𝐚 (Gujarat Based Firm) Bought electoral bonds worth Rs 77.5 crore between May 2019 till January 2024. Company’s antiplatelet medicine *** Deplatt-150 *** had failed the salicylic acid test and was declared substandard by the Maharashtra Food and Drug Administration in 2018. In October 2019, the #UnitedStates Food and Drug Administration issued a warning. However, the Gujarat government did not take any action against the pharmaceutical company. 📍𝐙𝐲𝐝𝐮𝐬 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 Purchased electoral bonds worth Rs 29 crore between 2022 and 2023. In 2021, the #Bihar drug regulator had declared a batch of remdesivir medicines manufactured by the #Gujarat-based company as “not of standard quality” after traces of bacterial endotoxin were found in them. Several patients were reported to have suffered adverse drug reactions from the medicines. But the #Gujarat drug regulator did not collect samples of these batches for further testing and nor did it initiate any action against the manufacturing unit of Zydus. Full Report: #ElectoralBondsScam ⚠️ If You Think The Culprits Should Be Punished then 𝐒𝐩𝐞𝐚𝐤 𝐔𝐩 & Share this Post #WorldTuberculosisDay #WorldTBDay #BJPFreezesIndianDemocracy #BJPkaSharabGhotala #Holi #Holi2024 #HoliSpecial

তন্ময় l T͞anmoy l

80,006 Aufrufe • vor 2 Jahren

Demis Hassabis says AI won’t just accelerate drug discovery. It will replace the process entirely. The pharmaceutical industry finds drugs the same way it has for decades. Synthesize a compound. Test it on animals. Test it on humans. Wait years for approval. Hope the molecule doesn’t kill someone along the way. Every step is physical. Every step is slow. Every step is expensive enough to make most diseases not worth curing. Hassabis: “We’re focusing on solving the rest of the drug discovery process, which is a lot of chemistry, designing the compounds, checking it’s not toxic, and all the different properties you need for drugs to be safe.” That sounds incremental. It isn’t. AlphaFold solved protein folding. Isomorphic Labs is now working through the rest of the chain. Compound design. Toxicity screening. Safety profiling. All computational. None of it requires a lab. Hassabis: “I think we’ll have that whole drug design engine ready in the next five to 10 years.” Not a tool that assists chemists. A system that replaces the chemistry. But designing the drug was never the bottleneck that killed people. Clinical trials were. A single drug takes over a decade to move from lab to patient. Most of that time isn’t science. It’s bureaucracy, logistics, and the blunt reality of testing molecules on living tissue one dose at a time. Hassabis: “Simulating parts of the human metabolism, also stratifying patients to make sure that certain patients get exactly the right type of drug that’s suitable for their genomic makeup.” Simulate the patient before you treat the patient. Map individual DNA. Model personal metabolism. Test the drug on a digital replica before it touches a vein. Not personalized medicine as a marketing phrase. Personalized medicine as an engineering output. The final wall is regulatory. The FDA exists because humans make mistakes with molecules. Every approval gate was built to catch errors that cost lives. The entire structure assumes the process is fallible. What happens when the process stops being fallible. Hassabis: “Perhaps like the animal testing is not needed anymore, maybe we can go up the dosage ladder quicker, because you can rely on these models.” He’s not speculating. He’s describing a sequence. AI-designed drugs enter the existing pipeline. A dozen compounds go through full traditional trials. Regulators collect data. They back-test model predictions against real outcomes. Hassabis: “Then the government and the regulatory bodies see that and they have enough data to sort of back-test the predictions of those models.” When the models prove more accurate than the trials they’re meant to replace, the trials become the bottleneck. Not the science. The paperwork. Animal testing shortened. Dosage ladders compressed. Entire stages of the pipeline collapsed into computation. The drug doesn’t get discovered faster. The drug gets discovered differently. The laboratory moves from a building to a server. The clinical trial moves from a hospital ward to a simulation. The patient moves from a statistic to a genome. Hassabis isn’t promising a cure for one disease. He’s describing the architecture that makes curing disease an engineering problem with a known solution path. The bottleneck was never biology. It was the speed at which humans were allowed to solve it. That speed limit is about to be revoked.

Dustin

43,980 Aufrufe • vor 6 Monaten